0000899243-22-026518.txt : 20220721 0000899243-22-026518.hdr.sgml : 20220721 20220721191206 ACCESSION NUMBER: 0000899243-22-026518 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220720 FILED AS OF DATE: 20220721 DATE AS OF CHANGE: 20220721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sinha Vikas CENTRAL INDEX KEY: 0001337845 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 221098138 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACUETICALS, INC. STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-20 0 0001754068 Allovir, Inc. ALVR 0001337845 Sinha Vikas C/O ALLOVIR, INC. 1100 WINTER STREET WALTHAM MA 02451 1 1 0 0 See Remarks Common Stock 2022-07-20 4 S 0 1432 5.2145 D 938224 D Common Stock 13420970 I See footnote Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Officer Title: President and Chief Financial Officer /s/ Brett Hagen, as Attorney-in-Fact 2022-07-21